32 episodes

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Brain & Behaviour Audio PeerVoice

    • Science

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Managing Generalised Myasthenia Gravis: A Tale of Two Targets

    Managing Generalised Myasthenia Gravis: A Tale of Two Targets

    Visit https://www.peervoice.com/WVF860 to view the entire programme with slides. After completing “Managing Generalised Myasthenia Gravis: A Tale of Two Targets”, participants will be able to: Summarise the pathogenic contributors in generalised myasthenia gravis (gMG) and their role in disease progression; Translate the clinical data for emerging therapies for uncontrolled gMG in the context of current clinical practice; and Appraise how emerging therapies could evolve the standard of care for patients with uncontrolled gMG.

    • 1 hr
    The Fear of Disappearing, the Fight to Stay Present': Understanding the Needs of Patients With Alzheimer's Disease

    The Fear of Disappearing, the Fight to Stay Present': Understanding the Needs of Patients With Alzheimer's Disease

    Visit https://www.peervoice.com/VDJ860 to view the entire programme with slides. After completing “The Fear of Disappearing, the Fight to Stay Present': Understanding the Needs of Patients With Alzheimer's Disease”, participants will be able to: Describe how a diagnosis of Alzheimer's disease (AD) can impact patients and hence the importance of patient collaboration and communication; and Identify practical approaches to shared decision-making between expert and patients with AD during treatment planning.

    • 15 min
    Managing Long-Chain Fatty Acid Disorders: Experience of Novel Therapies in the Real World

    Managing Long-Chain Fatty Acid Disorders: Experience of Novel Therapies in the Real World

    Visit https://www.peervoice.com/TAW860 to view the entire programme with slides. After completing “Managing Long-Chain Fatty Acid Disorders: Experience of Novel Therapies in the Real World”, participants will be able to: Describe the recent developments in the management of long-chain fatty acid oxidation disorders (LC-FAOD); Identify the patient characteristics and disease manifestations that would indicate a need to initiate a novel therapeutic approach to managing LC-FAOD; and Formulate practical approaches to optimise the management of patients with LC-FAOD on a novel therapy.

    • 24 min
    Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics

    Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics

    Visit https://www.peervoice.com/TMJ860 to view the entire programme with slides. After completing “Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics”, participants will be able to: Summarise key findings from the 24-month analysis of the ENVISION trial in patients with acute hepatic porphyria (AHP); Discuss the current practices and unmet needs for the long-term management of AHP; and Describe the impact of these data on clinical practice within the context of treatment paradigms for the long-term management of patients with AHP.

    • 32 min
    Treatment Goals in Systemic Lupus Erythematosus: How Are We Raising the Bar?

    Treatment Goals in Systemic Lupus Erythematosus: How Are We Raising the Bar?

    Visit https://www.peervoice.com/HVF860 to view the entire programme with slides. After completing “Treatment Goals in Systemic Lupus Erythematosus: How Are We Raising the Bar?”, participants will be able to: Summarise the potential consequences of not achieving disease control in patients with systemic lupus erythematosus (SLE); Discuss the latest clinical guidelines for the therapeutic management of patients with moderate-to-severe SLE in the context of achieving the goals aligned with clinical remission; and Propose opportunities to optimise management of patients with moderate-to-severe SLE using treatment strategies geared towards prevention of long-term organ damage.

    • 45 min
    Suspecting and Diagnosing Inherited Retinal Dystrophies: Early Clues and Confirmatory Testing

    Suspecting and Diagnosing Inherited Retinal Dystrophies: Early Clues and Confirmatory Testing

    Visit https://www.peervoice.com/ZHA860 to view the entire programme with slides. After completing “Suspecting and Diagnosing Inherited Retinal Dystrophies: Early Clues and Confirmatory Testing”, participants will be able to: Recognize factors that may indicate inherited retinal dystrophies (IRDs), such as symptoms and family history; Describe genetic causes of IRDs; Propose pathways for diagnosing IRDs and identify when patients may benefit from genetic testing for optimal diagnosis.

    • 20 min

More by PeerVoice

PeerVoice
PeerVoice
PeerVoice
PeerVoice
PeerVoice
PeerVoice